The FDA's drug approvals database records an approved supplement dated 18 September 2026 to the new drug application for abemaciclib (Verzenio), held by Eli Lilly. The entry does not describe what the supplement changed.
Supplements can cover anything from a labelling or manufacturing update to a new indication. Without the label text, it cannot be assumed to be a new use.
Any change in US labelling does not automatically alter prescribing information approved by CDSCO in India. Oncologists prescribing it should check the current US label for any updated dosing or safety wording.
- An FDA supplement approval is not necessarily a new indication.
- Check the current label for any updated safety or dosing language.
- US label changes do not automatically apply to Indian prescribing information.
- Continue current monitoring for diarrhoea, neutropenia, liver function and venous thromboembolism.
Why it matters
Label updates to a widely used CDK4/6 inhibitor can quietly change monitoring advice.
Don't overread it
A licence supplement is not a new indication; the record gives no detail of the change.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free